Related Experiment Videos
[Beta-adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy]
Insights
Beta-blockers and calcium antagonists offer quality of life improvements for some hypertrophic cardiomyopathy patients. However, these drugs do not reduce myocardial hypertrophy and carry specific risks, with nifedipine notably increasing lethality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HC) is a complex cardiac condition.
- Pharmacological interventions aim to manage symptoms and improve patient outcomes.
Purpose of the Study:
- To evaluate the effects of beta-blockers (propranolol, penbutolol) and calcium antagonists (nifedipine, verapamil, diltiazem) in patients with hypertrophic cardiomyopathy.
- To assess the impact of these drugs on quality of life, myocardial hypertrophy, contractility, ejection fraction, and survival.
Main Methods:
- Clinical data, electrocardiogram (ECG), and echocardiography (echo-CG) findings were assessed in 73 patients with HC.
- Comparative analysis of treatment effects between different beta-blockers and calcium antagonists.
Main Results:
- Both beta-adrenoblockers and calcium antagonists improved quality of life in approximately one-third of patients; penbutolol and nifedipine were effective in half.
- Neither drug class reduced myocardial hypertrophy. Calcium antagonists potentially decreased myocardial contractility, while beta-blockers could increase ejection fraction.
- Diltiazem showed positive effects on diastolic function but had numerous side effects. Nifedipine was associated with increased lethality compared to verapamil and propranolol.
Conclusions:
- Beta-blockers and calcium antagonists can enhance quality of life in a subset of hypertrophic cardiomyopathy patients.
- These medications do not reverse myocardial hypertrophy. Careful selection is crucial due to differential effects on contractility, ejection fraction, and particularly lethality associated with nifedipine.
Abstract:
Effects of beta-blockers (propranolol, penbutolol) and calcium antagonists (nifedipine, verapamil, diltiazem) were studied in 73 patients with hypertrophic cardiomyopathy (HC). Clinical data, ECG and echo-CG findings were assessed. It was found that beta-adrenoblockers and calcium antagonists improve quality of life in one-third of the patients. Penbutolol and nifedipine did so in half of the patients. Neither beta-adrenoblockers nor calcium antagonists decrease myocardial hypertrophy. Calcium antagonists may result in lowering of myocardial contractility while beta-adrenoblockers may increase the ejection fraction. Diltiazem produced a positive effect on diastolic function but had many side effects. Nifedipine increased lethality compared with verapamil and propranolol.